You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

CLINICAL TRIALS PROFILE FOR MANNITOL 10%


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Mannitol 10%

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00111956 ↗ Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed Massachusetts General Hospital Phase 2/Phase 3 2004-04-01 Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00003062 ↗ Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 1997-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed Johns Hopkins University Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed National Center for Research Resources (NCRR) Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 4 of 4 entries

Clinical Trial Conditions for Mannitol 10%

Condition Name

2010760-20246810121416182022AsthmaCystic FibrosisHealthyTraumatic Brain Injury[disabled in preview]
Condition Name for Mannitol 10%
Intervention Trials
Asthma 20
Cystic Fibrosis 10
Healthy 7
Traumatic Brain Injury 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

231210100-2024681012141618202224AsthmaIntracranial HypertensionBrain NeoplasmsFibrosis[disabled in preview]
Condition MeSH for Mannitol 10%
Intervention Trials
Asthma 23
Intracranial Hypertension 12
Brain Neoplasms 10
Fibrosis 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mannitol 10%

Trials by Country

+
Trials by Country for Mannitol 10%
Location Trials
United States 137
Canada 38
United Kingdom 35
Australia 34
Italy 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for Mannitol 10%
Location Trials
New York 19
Massachusetts 12
Minnesota 9
Oregon 8
Ohio 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mannitol 10%

Clinical Trial Phase

30.3%27.9%8.2%33.6%010152025303540Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for Mannitol 10%
Clinical Trial Phase Trials
Phase 4 37
Phase 3 34
Phase 2/Phase 3 10
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

68.0%13.9%9.3%8.8%020406080100120140CompletedUnknown statusNot yet recruiting[disabled in preview]
Clinical Trial Status for Mannitol 10%
Clinical Trial Phase Trials
Completed 132
Unknown status 27
Not yet recruiting 18
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mannitol 10%

Sponsor Name

trials02468101214161820PharmaxisNorthwell HealthNational Cancer Institute (NCI)[disabled in preview]
Sponsor Name for Mannitol 10%
Sponsor Trials
Pharmaxis 19
Northwell Health 7
National Cancer Institute (NCI) 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

81.0%14.2%0050100150200250300350400OtherIndustryNIH[disabled in preview]
Sponsor Type for Mannitol 10%
Sponsor Trials
Other 366
Industry 64
NIH 17
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Mannitol 10%: Clinical Trials, Market Analysis, and Projections

Introduction

Mannitol, a sugar alcohol, is widely used in medical and industrial applications. This article delves into the recent clinical trials, market analysis, and future projections for Mannitol 10%, focusing on its medical uses.

Clinical Trials: Mannitol in Medical Applications

ADAPT Trial: Hypertonic Saline vs. Mannitol

A significant clinical trial, the ADAPT trial, published in the JAMA Open Network, compared the effects of hypertonic saline and mannitol on intracranial pressure (ICP) in children with severe traumatic brain injury. The trial involved 518 patients and nearly 2,500 boluses of either hypertonic saline or mannitol.

  • Key Findings: The study showed that both hypertonic saline and mannitol were effective in lowering ICP, but hypertonic saline appeared to be more effective in this context. However, the data also supported the use of mannitol, particularly in scenarios where hypertonic saline is not available or suitable[1].

  • Limitations: The study highlighted limitations, such as the dominance of data from a few centers and the inability to compare different doses of hypertonic saline comprehensively. Despite these limitations, the study is expected to influence future guidelines on the management of pediatric traumatic brain injury[1].

Cisplatin-Induced Nephrotoxicity

Another clinical study evaluated the use of mannitol to prevent cisplatin-induced nephrotoxicity in patients. This prospective study compared patients treated with cisplatin alone versus those treated with cisplatin and mannitol.

  • Results: The study found no significant difference in the increase in serum creatinine or the incidence of acute nephrotoxicity between the two groups. However, there was a non-significant trend towards lower rates of nephrotoxicity in patients receiving higher doses of cisplatin with mannitol[4].

Market Analysis

Current Market Size

As of 2022, the global mannitol market was estimated to be around $418.65 million[2].

Growth Projections

The market is projected to grow significantly over the next decade:

  • Forecast Period 2023-2033: The market is expected to reach $890.31 million with a Compound Annual Growth Rate (CAGR) of 7.1%[2].
  • Alternative Forecast: Another report suggests the market will reach $584.47 million by 2030, growing at a CAGR of 4.9% from 2023 to 2030[5].

Key Drivers

Several factors are driving the growth of the mannitol market:

  • Increasing Demand for Low-Calorie Sweeteners: The rising incidence of diabetes and obesity is leading to increased demand for low-calorie sweeteners like mannitol. Its application in the food and beverages sector, particularly in baked goods and confectionery, is on the rise[2][5].
  • Pharmaceutical Applications: Mannitol is used as an excipient in pharmaceutical formulations and for treating various medical conditions, including brain, kidney, and heart problems. Its use in hospital pharmacies, retail pharmacies, and online pharmacies is significant[5].
  • Consumer Health Consciousness: The growing awareness of health issues and the preference for non-cariogenic and low-calorie additives are propelling the demand for mannitol[2].

Regional Analysis

The market growth is distributed across various regions:

  • Asia Pacific and Middle East: These regions are seeing increased research and development activities, leading to new product launches and collaborations between regional and global players[2].
  • North America and Europe: These regions also show significant growth, driven by consumer demand for health-conscious products and the expanding pharmaceutical sector[5].

Market Segmentation

By Product Type

The global mannitol market is segmented based on product type:

  • Concentrations: The market includes various concentrations such as 5g/100 ml, 10g/100 ml, 15g/100 ml, 20g/100 ml, and 25g/100 ml. The 20g/100 ml concentration is expected to represent the largest revenue share due to its use in treating increased intracranial pressure, glaucoma, and other medical conditions[5].

By Application

The market is also segmented by application:

  • Hospital Pharmacies: Mannitol is widely used in hospital settings for various medical treatments.
  • Retail Pharmacies: It is available in retail pharmacies for both medical and non-medical uses.
  • Online Pharmacies: The online segment is growing due to increased consumer convenience and accessibility[5].

Challenges and Opportunities

Challenges

  • Regulatory Environment: Changes in regulatory environments can impact the market. For instance, new permissions for sweeteners in bakery, confectionery, and dairy products have influenced the market positively, but any reversals could pose challenges[2].
  • Competition: The market faces competition from other sugar alcohols and sweeteners, which could affect mannitol's market share[2].

Opportunities

  • Growing Health Awareness: Increasing consumer health consciousness and the demand for low-calorie, non-cariogenic sweeteners present significant opportunities for the mannitol market[2].
  • Expanding Pharmaceutical Uses: The use of mannitol in pharmaceutical formulations and its potential in new medical applications offer further growth opportunities[5].

Key Takeaways

  • Clinical Trials: Recent trials like the ADAPT trial and the study on cisplatin-induced nephrotoxicity provide valuable insights into mannitol's efficacy and limitations.
  • Market Growth: The mannitol market is projected to grow significantly, driven by increasing demand for low-calorie sweeteners and its pharmaceutical applications.
  • Regional Expansion: The market is expanding across various regions, with Asia Pacific and the Middle East showing promising growth.
  • Segmentation: The market is segmented by product type and application, with the 20g/100 ml concentration and hospital pharmacies being key segments.

FAQs

What is the current market size of the global mannitol market?

The global mannitol market was estimated to be around $418.65 million in 2022[2].

What is the projected growth rate of the mannitol market from 2023 to 2033?

The market is expected to grow at a CAGR of 7.1% from 2023 to 2033, reaching $890.31 million by 2033[2].

What are the primary drivers of the mannitol market growth?

The primary drivers include increasing demand for low-calorie sweeteners, growing consumer health consciousness, and expanding pharmaceutical applications[2][5].

Which concentration of mannitol is expected to represent the largest revenue share?

The 20g/100 ml concentration is expected to represent the largest revenue share due to its use in treating various medical conditions[5].

What are the key segments of the mannitol market by application?

The key segments include hospital pharmacies, retail pharmacies, and online pharmacies[5].

Sources

  1. YouTube: "Results of Hypertonic Saline or Mannitol Clinical Trial for Treatment of Pediatric TBI" by World Shared Practice Forum.
  2. Future Market Insights: "Mannitol Market Size, Share, Outlook & Forecast by 2033."
  3. IndustryARC: "Mannitol Market 2020 - 2025."
  4. BMJ: "CP-136 Mannitol 10% for the prevention of cisplatin induced nephrotoxicity."
  5. SNS Insider: "Mannitol Market Size & Share Report Forecast 2023-2030."

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.